Back Article

Akerstrom, S., Tan, Y.J.,Mirazimi, A., 2006. Amino acids 15-28 in the ectodomain of SARS coronavirus 3a protein induces neutralizing antibodies. FEBS Lett., 580, 3799-3803.

Arshad, N., Laurent-Rolle, M., Ahmed, W.S., Hsu, J.C., Mitchell, S.M., Pawlak, J., Sengupta, D., Biswas, K.H.,Cresswell, P., 2022. SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to downregulate MHC-I surface expression. bioRxiv, 10.1101/2022.05.17.492198.

Bacher, P., Rosati, E., Esser, D., Martini, G.R., Saggau, C., Schiminsky, E., Dargvainiene, J., Schroder, I., Wieters, I., Khodamoradi, Y., Eberhardt, F., Vehreschild, M., Neb, H., Sonntagbauer, M., Conrad, C., Tran, F., Rosenstiel, P., Markewitz, R., Wandinger, K.P., Augustin, M., Rybniker, J., Kochanek, M., Leypoldt, F., Cornely, O.A., Koehler, P., Franke, A.,Scheffold, A., 2020. Low-avidity CD4(+) T cell responses to SARS-CoV-2 in unexposed individuals and humans with severe COVID-19. Immunity, 53, 1258-1271.e1255.

Blanco-Melo, D., Nilsson-Payant, B.E., Liu, W.C., Uhl, S., Hoagland, D., Moeller, R., Jordan, T.X., Oishi, K., Panis, M., Sachs, D., Wang, T.T., Schwartz, R.E., Lim, J.K., Albrecht, R.A.,Tenoever, B.R., 2020. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell, 181, 1036-1045.e1039.

Bojkova, D., Klann, K., Koch, B., Widera, M., Krause, D., Ciesek, S., Cinatl, J.,Munch, C., 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature, 583, 469-472.

Burbelo, P.D., Ching, K.H., Klimavicz, C.M.,Iadarola, M.J., 2009. Antibody profiling by Luciferase Immunoprecipitation Systems (LIPS). J. Vis. Exp., 10.3791/1549.

Deming, D., Sheahan, T., Heise, M., Yount, B., Davis, N., Sims, A., Suthar, M., Harkema, J., Whitmore, A., Pickles, R., West, A., Donaldson, E., Curtis, K., Johnston, R.,Baric, R., 2006. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med., 3, e525.

Gordon, D.E., Jang, G.M., Bouhaddou, M., Xu, J., Obernier, K., White, K.M., O'Meara, M.J., Rezelj, V.V., Guo, J.Z., Swaney, D.L., et al., 2020. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature, 583, 459-468.

Hachim, A., Gu, H., Kavian, O., Kwan, M.Y., Chan, W.H., Yau, Y.S., Chiu, S.S., Tsang, O.T., Hui, D.S., Ma, F., Lau, E.H., Cheng, S.M., Poon, L.L., Peiris, J.M., Valkenburg, S.A.,Kavian, N., 2021. The SARS-CoV-2 antibody landscape is lower in magnitude for structural proteins, diversified for accessory proteins and stable long-term in children. medRxiv, 10.1101/2021.01.03.21249180.

Hachim, A., Gu, H., Kavian, O., Mori, M., Kwan, M.Y.W., Chan, W.H., Yau, Y.S., Chiu, S.S., Tsang, O.T.Y., Hui, D.S.C., Mok, C.K.P., Ma, F.N.L., Lau, E.H.Y., Amarasinghe, G.K., Qavi, A.J., Cheng, S.M.S., Poon, L.L.M., Peiris, J.S.M., Valkenburg, S.A.,Kavian, N., 2022. SARS-CoV-2 accessory proteins reveal distinct serological signatures in children. Nat. Commun., 13, 2951.

Hachim, A., Kavian, N., Cohen, C.A., Chin, A.W.H., Chu, D.K.W., Mok, C.K.P., Tsang, O.T.Y., Yeung, Y.C., Perera, R., Poon, L.L.M., Peiris, J.S.M.,Valkenburg, S.A., 2020. ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection. Nat. Immunol., 21, 1293-1301.

Han, L., Zhuang, M.W., Deng, J., Zheng, Y., Zhang, J., Nan, M.L., Zhang, X.J., Gao, C.,Wang, P.H., 2021. SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways. J. Med. Virol., 93, 5376-5389.

Huang, C., Ito, N., Tseng, C.T.,Makino, S., 2006. Severe acute respiratory syndrome coronavirus 7a accessory protein is a viral structural protein. J. Virol., 80, 7287-7294.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., Gao, H., Guo, L., Xie, J., Wang, G., Jiang, R., Gao, Z., Jin, Q., Wang, J.,Cao, B., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395, 497-506.

Ito, N., Mossel, E.C., Narayanan, K., Popov, V.L., Huang, C., Inoue, T., Peters, C.J.,Makino, S., 2005. Severe acute respiratory syndrome coronavirus 3a protein is a viral structural protein. J. Virol., 79, 3182-3186.

Jiang, H.W., Zhang, H.N., Meng, Q.F., Xie, J., Li, Y., Chen, H., Zheng, Y.X., Wang, X.N., Qi, H., Zhang, J., Wang, P.H., Han, Z.G.,Tao, S.C., 2020. SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70. Cell. Mol. Immunol., 17, 998-1000.

Kim, D., Lee, J.Y., Yang, J.S., Kim, J.W., Kim, V.N.,Chang, H., 2020. The architecture of SARS-CoV-2 transcriptome. Cell, 181, 914-921.e910.

Konno, Y., Kimura, I., Uriu, K., Fukushi, M., Irie, T., Koyanagi, Y., Sauter, D., Gifford, R.J., Nakagawa, S.,Sato, K., 2020. SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is increased by a naturally occurring elongation variant. Cell Rep., 32, 108185.

Lam, J.Y., Yuen, C.K., Ip, J.D., Wong, W.M., To, K.K., Yuen, K.Y.,Kok, K.H., 2020. Loss of orf3b in the circulating SARS-CoV-2 strains. Emerg. Microbes Infect., 9, 2685-2696.

Li, J.Y., Liao, C.H., Wang, Q., Tan, Y.J., Luo, R., Qiu, Y.,Ge, X.Y., 2020. The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. Virus Res., 286, 198074.

Li, Y., Xu, Z., Lei, Q., Lai, D.Y., Hou, H., Jiang, H.W., Zheng, Y.X., Wang, X.N., Wu, J., Ma, M.L., Zhang, B., Chen, H., Yu, C., Xue, J.B., Zhang, H.N., Qi, H., Guo, S.J., Zhang, Y., Lin, X., Yao, Z., Sheng, H., Sun, Z., Wang, F., Fan, X.,Tao, S.C., 2021. Antibody landscape against SARS-CoV-2 reveals significant differences between non-structural/accessory and structural proteins. Cell Rep., 36, 109391.

Liu, T., Jia, P., Fang, B.,Zhao, Z., 2020. Differential expression of viral transcripts from single-cell RNA sequencing of moderate and severe COVID-19 patients and its implications for case severity. Front. Microbiol., 11, 603509.

Matsuoka, K., Imahashi, N., Ohno, M., Ode, H., Nakata, Y., Kubota, M., Sugimoto, A., Imahashi, M., Yokomaku, Y.,Iwatani, Y., 2022. SARS-CoV-2 accessory protein ORF8 is secreted extracellularly as a glycoprotein homodimer. J. Biol. Chem., 298, 101724.

Minakshi, R., Padhan, K., Rani, M., Khan, N., Ahmad, F.,Jameel, S., 2009. The SARS Coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor. PLoS One, 4, e8342.

Miorin, L., Kehrer, T., Sanchez-Aparicio, M.T., Zhang, K., Cohen, P., Patel, R.S., Cupic, A., Makio, T., Mei, M., Moreno, E., Danziger, O., White, K.M., Rathnasinghe, R., Uccellini, M., Gao, S., Aydillo, T., Mena, I., Yin, X., Martin-Sancho, L., Krogan, N.J., Chanda, S.K., Schotsaert, M., Wozniak, R.W., Ren, Y., Rosenberg, B.R., Fontoura, B.M.A.,Garcia-Sastre, A., 2020. SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proc. Natl. Acad. Sci. U. S. A., 117, 28344-28354.

Pushko, P., Parker, M., Ludwig, G.V., Davis, N.L., Johnston, R.E.,Smith, J.F., 1997. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology, 239, 389-401.

Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W.,Tian, D.S., 2020. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis., 71, 762-768.

Ren, Y., Shu, T., Wu, D., Mu, J., Wang, C., Huang, M., Han, Y., Zhang, X.Y., Zhou, W., Qiu, Y.,Zhou, X., 2020. The ORF3a protein of SARS-CoV-2 induces apoptosis in cells. Cell. Mol. Immunol., 17, 881-883.

Sharma, K., Akerstrom, S., Sharma, A.K., Chow, V.T., Teow, S., Abrenica, B., Booth, S.A., Booth, T.F., Mirazimi, A.,Lal, S.K., 2011. SARS-CoV 9b protein diffuses into nucleus, undergoes active Crm1 mediated nucleocytoplasmic export and triggers apoptosis when retained in the nucleus. PLoS One, 6, e19436.

Sun, J., Zhuang, Z., Zheng, J., Li, K., Wong, R.L., Liu, D., Huang, J., He, J., Zhu, A., Zhao, J., Li, X., Xi, Y., Chen, R., Alshukairi, A.N., Chen, Z., Zhang, Z., Chen, C., Huang, X., Li, F., Lai, X., Chen, D., Wen, L., Zhuo, J., Zhang, Y., Wang, Y., Huang, S., Dai, J., Shi, Y., Zheng, K., Leidinger, M.R., Chen, J., Li, Y., Zhong, N., Meyerholz, D.K., Mccray, P.B., Jr., Perlman, S.,Zhao, J., 2020. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell, 182, 734-743.e735.

Tan, M., Liu, Y., Zhou, R., Deng, X., Li, F., Liang, K.,Shi, Y., 2020. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology, 160, 261-268.

Tang, Z., Yu, P., Guo, Q., Chen, M., Lei, Y., Zhou, L., Mai, W., Chen, L., Deng, M., Kong, W., Niu, C., Xiong, X., Li, W., Chen, C., Lai, C., Wang, Q., Li, B.,Ji, T., 2023. Clinical characteristics and host immunity responses of SARS-CoV-2 Omicron variant BA.2 with deletion of ORF7a, ORF7b and ORF8. Virol. J., 20, 106.

Wang, G., Guan, J., Li, G., Wu, F., Yang, Q., Huang, C., Shao, J., Xu, L., Guo, Z., Zhou, Q., Zhu, H.,Chen, Z., 2021. Effect of ORF7 of SARS-CoV-2 on the chemotaxis of monocytes and neutrophils in vitro. Dis. Markers, 2021, 6803510.

Wu, A., Peng, Y., Huang, B., Ding, X., Wang, X., Niu, P., Meng, J., Zhu, Z., Zhang, Z., Wang, J., Sheng, J., Quan, L., Xia, Z., Tan, W., Cheng, G., Jiang, T., 2020. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 27, 325–328.

Wu, F., Zhao, S., Yu, B., Chen, Y.M., Wang, W., Song, Z.G., Hu, Y., Tao, Z.W., Tian, J.H., Pei, Y.Y., Yuan, M.L., Zhang, Y.L., Dai, F.H., Liu, Y., Wang, Q.M., Zheng, J.J., Xu, L., Holmes, E.C.,Zhang, Y.Z., 2020. A new coronavirus associated with human respiratory disease in China. Nature, 579, 265-269.

Wu, J., Shi, Y., Pan, X., Wu, S., Hou, R., Zhang, Y., Zhong, T., Tang, H., Du, W., Wang, L., Wo, J., Mu, J., Qiu, Y., Yang, K., Zhang, L.K., Ye, B.C.,Qi, N., 2021. SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO. Cell Rep., 34, 108761.

Yang, R., Zhao, Q., Rao, J., Zeng, F., Yuan, S., Ji, M., Sun, X., Li, J., Yang, J., Cui, J., Jin, Z., Liu, L.,Liu, Z., 2021. SARS-CoV-2 accessory protein ORF7b mediates tumor necrosis factor-α-induced apoptosis in cells. Front. Microbiol., 12, 654709.

Zhang, J., Cruz-Cosme, R., Zhuang, M.W., Liu, D., Liu, Y., Teng, S., Wang, P.H.,Tang, Q., 2020. A systemic and molecular study of subcellular localization of SARS-CoV-2 proteins. Signal Transduct. Target. Ther., 5, 269.

Zhang, Y., Chen, Y., Li, Y., Huang, F., Luo, B., Yuan, Y., Xia, B., Ma, X., Yang, T., Yu, F., Liu, J., Liu, B., Song, Z., Chen, J., Yan, S., Wu, L., Pan, T., Zhang, X., Li, R., Huang, W., He, X., Xiao, F., Zhang, J.,Zhang, H., 2021. The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Ι. Proc. Natl. Acad. Sci. U. S. A., 118.

Zhao, J., Zhao, J., Mangalam, A.K., Channappanavar, R., Fett, C., Meyerholz, D.K., Agnihothram, S., Baric, R.S., David, C.S.,Perlman, S., 2016. Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity, 44, 1379-1391.